Discontinuation of immune checkpoint inhibitors in hepatocellular carcinoma: a retrospective cohort study.

ABSTRACT:

Background

The optimal timing to discontinue immune checkpoint inhibitor (ICI) therapy in hepatocellular carcinoma (HCC) patients with clinical benefits remains unclear. This study aimed to assess the outcomes of HCC patients after ICI discontinuation.

Methods

Patients with HCC were retrospectively screened and those discontinued ICI therapy in the absence of progressive disease (PD) were included. Responses at discontinuation were evaluated per response evaluation criteria in solid tumors (RECIST) version 1.1 and modified RECIST (mRECIST). Patients were classified into five subgroups according to the cause of discontinuation: complete response (CR), partial response (PR), stable disease (SD) per RESICT version 1.1, adverse event (AE), or others. Progression-free survival (P

SUBMITTER: Zhou L 

PROVIDER: S-EPMC11399828 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature